肝胆胰系肿瘤外周血CD146 mRNA表达与小剂量化疗预后的关系  

Peripheral blood CD146 mRNA expression levels in prognosis of patients with hepatoma,carcinoma of gallbladder,pancreatic cancer with metronomic chemotherapy

作　　者：钱晓萍[1] 刘宝瑞[1] 孙永臣[1] 胡文静[1] 胡静[1] 孔炜伟[1] 杨阳[1] 

机构地区：[1]南京大学附属鼓楼医院肿瘤中心,江苏南京210008

出　　处：《现代肿瘤医学》2009年第8期1505-1508,共4页Journal of Modern Oncology

基　　金：江苏省自然基金(BK2006005)

摘　　要：目的:观察肝胆胰系肿瘤患者外周血中CD146 mRNA表达水平与小剂量化疗预后的关系。方法:RT-PCR方法检测24例肝癌、胆囊(管)癌、胰腺癌患者外周血中CD146 mRNA表达,分为高表达组和低表达组,采用低剂量多西紫杉醇(TXT20mg静滴d1、5、9、13)及环磷酰胺(CTX50mg口服d1-13)方案治疗两周期以上,比较两组治疗的近期临床疗效、临床受益率、生存期。结果:小剂量化疗的临床控制率为75.0%,临床受益率为58.33%,中位生存时间11.5个月,1年生存率45.81%。CD146 mRNA高表达组的中位生存期为11个月,1年生存率41.67%;CD146 mRNA低表达组的中位生存期12个月,1年生存率50.0%,两组比较没有统计学差异(P>0.05),CD146的表达与总生存时间之间没有相关性(P=0.513)。结论:肝胆胰系肿瘤患者外周血中CD146 mRNA表达可能不能成为小剂量化疗的预后预测因子;小剂量化疗能提高肝胆胰系肿瘤治疗的临床控制率,改善临床受益,延长生存期,而无明显的不良反应。Objective：To investigate the correlation of the peripheral blood CD146 mRNA expression levels in prognosis of patients with hepatoma, carcinoma of gallbladder, pancreatic cancer with metronomic chemotherapy. Methods：By real -time quantitative reverse transcriptase polymerase chain reaction to detect CD146 mRNA expression levels of peripheral blood in patients with hepatoma, carcinoma of gallbladder, pancreatic cancer. Low - dose docetaxel （intravenous TXT 20mg d1、5、9、13 ） ,and cyclophosphamide （CTX 50mg oral d1-13 ） were used in the treatment for more than two cycles. Results：The metronomic chemotherapy was used for twenty four patients and clinical control rate was 75.0%, clinical benefit rate was 58.33% ; the median survival time was 11.5 months, one year survival rate was 45.81%. The median survival period of CD146 mRNA high expression group was 11 months,one year survival rate was 41.67% ; The median survival period of CD146 mRNA low expression was 12 months,one year survival rate was 50.0% （ P 〉 0.05 ）, and CD146 expression and overall survival time was not correlated （ P = 0. 513 ）. Conclusion：CD146 mRNA expression level in the peripheral blood of patients with hepatoma, carcinoma of gallbladder, pancreatic cancer may not be a favorable indicator for overall survival in the use of metronomic chemotherapy. This metronomic chemotherapy could raise clinical control rate, improve clinical benefit, prolong survival time to patients with hepatoma, carcinoma of gallbladder, pancreatic cancer, without obvious side effects.

关 键 词：多西紫杉醇 环磷酰胺 CD146 mRNA 小剂量化疗 肿瘤 

分 类 号：R730.3[医药卫生—肿瘤]